Impact of apixaban treatment discontinuation on the risk of hospitalization among patients with nonvalvular atrial fibrillation and COVID-19

References

• Gopinathannair R, Merchant FM, Lakkireddy DR, et al. COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies. J Interv Card Electrophysiol. 2020;59(2):329–336.
   PubMed Web of Science ®Google Scholar
• Hu YF, Cheng WH, Hung Y, et al. Management of atrial fibrillation in COVID-19 pandemic. Circ J. 2020;84(10):1679–1685.
   PubMed Web of Science ®Google Scholar
• Rattanawong P, Shen W, El Masry H, et al. Guidance on short-term management of atrial fibrillation in coronavirus disease 2019. J Am Heart Assoc. 2020;9(14):e017529.
   PubMed Web of Science ®Google Scholar
• Harrison SL, Fazio-Eynullayeva E, Lane DA, et al. Atrial fibrillation and the risk of 30-day incident thromboembolic events, and mortality in adults ≥ 50 years with COVID-19. J Arrhythmia. 2021;37(1):231–237.
   PubMed Web of Science ®Google Scholar
• Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020;75(18):2352–2371.
   PubMed Web of Science ®Google Scholar
• Bosch NA, Cimini J, Walkey AJ. Atrial fibrillation in the ICU. Chest. 2018;154(6):1424–1434.
   PubMed Web of Science ®Google Scholar
• Gawałko M, Kapłon-Cieślicka A, Hohl M, et al. COVID-19 associated atrial fibrillation: incidence, putative mechanisms and potential clinical implications. Int J Cardiol Heart Vasc. 2020;30:100631.
   PubMed Web of Science ®Google Scholar
• Shea JB, Sears SF. A patient’s guide to living with atrial fibrillation. Circulation. 2008;117(20):e340–e343.
   PubMed Web of Science ®Google Scholar
• Rivera-Caravaca JM, Esteve-Pastor MA, Roldán V, et al. Non-vitamin K antagonist oral anticoagulants: Impact of non-adherence and discontinuation. Expert Opin Drug Saf. 2017;16(9):1051–1062.
   PubMed Web of Science ®Google Scholar
• Dietrich F, Polymeris AA, Verbeek M, et al. Impact of the COVID-19 lockdown on the adherence of stroke patients to direct oral anticoagulants: a secondary analysis from the MAAESTRO study. J Neurol. 2022;269(1):19–17.
   PubMed Web of Science ®Google Scholar
• Clinformatics Data Mart. Optum website [Internet] [updated 2017 Oct; cited 2021 Feb 10]. https://www.optum.com/content/dam/optum/resources/productSheets/Clinformatics_for_Data_Mart.pdf.
   Google Scholar
• Thigpen JL, Dillon C, Forster KB, et al. Validity of international classification of disease codes to identify ischemic stroke and intracranial hemorrhage among individuals with associated diagnosis of atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2015;8(1):8–14.
   PubMed Web of Science ®Google Scholar
• Cunningham A, Stein CM, Chung CP, et al. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf. 2011;20(6):560–566.
   PubMed Web of Science ®Google Scholar
• Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661–3679.
   PubMed Web of Science ®Google Scholar
• Thoemmes F, Ong AD. A primer on inverse probability of treatment weighting and marginal structural models. Emerg Adulthood. 2016;4(1):40–59.
   Web of Science ®Google Scholar
• Xu S, Ross C, Raebel MA, et al. Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. Value Health. 2010;13(2):273–277.
   PubMed Web of Science ®Google Scholar
• Austin PC. The use of propensity score methods with survival or time‐to‐event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med. 2014;33(7):1242–1258.
   PubMed Web of Science ®Google Scholar
• Dhamane AD, Hernandez I, Di Fusco M, et al. Non-persistence to oral anticoagulation treatment in patients with non-valvular atrial fibrillation in the USA. Am J Cardiovasc Drugs. 2022;22(3):333–343.
   PubMed Web of Science ®Google Scholar
• Ozaki AF, Choi AS, Le QT, et al. Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2020;13(3):e005969.
   PubMed Web of Science ®Google Scholar
• Lowres N, Giskes K, Hespe C, et al. Reducing stroke risk in atrial fibrillation: adherence to guidelines has improved, but patient persistence with anticoagulant therapy remains suboptimal. Korean Circ J. 2019;49(10):883–907.
   PubMed Web of Science ®Google Scholar
• Clement J, Jacobi M, Greenwood BN. Patient access to chronic medications during the covid-19 pandemic: evidence from a comprehensive dataset of US insurance claims. PLoS One. 2021;16(4):e0249453.
   PubMed Web of Science ®Google Scholar
• Racette L, Abu SL, Poleon S, et al. The impact of the COVID-19 pandemic on adherence to ocular hypotensive medication in patients with primary open-angle glaucoma. Ophthalmology. 2021;S0161–6420(21):00786–00787.
   Google Scholar
• Romiti GF, Corica B, Lip GYH, et al. Prevalence and impact of atrial fibrillation in hospitalized patients with COVID-19: a systematic review and meta-analysis. JCM. 2021;10(11):2490.
   Web of Science ®Google Scholar
• Zuin M, Rigatelli G, Bilato C, et al. Pre-existing atrial fibrillation is associated with increased mortality in COVID-19 patients. J Interv Card Electrophysiol. 2021;62(2):231–238.
   PubMed Web of Science ®Google Scholar
• Musikantow DR, Turagam MK, Sartori S, et al. Atrial fibrillation in patients hospitalized with COVID-19: incidence, predictors, outcomes, and comparison to influenza. JACC Clin Electrophysiol. 2021;7(9):1120–1130.
   PubMedGoogle Scholar
• Tomaszuk-Kazberuk A, Koziński M, Domienik-Karłowicz J, et al. Pharmacotherapy of atrial fibrillation in COVID-19 patients. Cardiol J. 2021;28(5):758–766.
   PubMed Web of Science ®Google Scholar